Rise in the incidence of skin cancer and focus on targeted therapy are the factors basically responsible for the growth of melanoma therapeutics market. Presence of a robust pipeline of drugs and biologics is expected to determine progression of melanoma therapeutics landscape during the forecast period. Generic drugs are likely to add to the revenue in low- and middle-income countries.
The companies operating in the melanoma therapeutics market are involved in exploring the potential of extracellular vesicles as the delivery vehicles to treat melanoma. They are also looking forward to analyze the data obtained from trial of melanoma therapy for the past three years in order to come up with advanced versions of therapeutics for melanoma.
The U.S. Environmental Protection Agency states that depletion of ozone layer at regular intervals is increasing the volume of UV rays reaching the earth, which is playing a crucial role in developing melanoma, a type of skin cancer. This factor is basically expected to drive demand for melanoma therapeutics.
These days, early detection treatments with minimal side-effects are being made available. An amalgamation of such therapies ascertains survival. Moreover, growing public awareness results in the key players investing more in research on this count.
The American Cancer Society states that risk of melanoma rises with age and is likely to affect people aged 60 and above.
Out of branded and generic drugs, the latter category is expected to hold a larger market share during the forecast period, especially due to the cost-effectiveness involved. According to the National Cancer Institute (NCI), desmoplastic melanoma can be treated through a single immunotherapy drug called Keytruda as per Phase II clinical trials.
| Attribute | Detail |
|---|---|
| Melanoma Therapeutics Industry Drivers |
|
Melanoma happens on healthy melanocytes changing into cancer cells. The melanocytes are skin cells that produce melanin, i.e. the pigment that imparts skin its color.
Melanoma drugs target proteins in the immune system that are turned off by melanoma cells. These drugs repair proteins so that the immune system can attack melanoma cells. One of the drugs to treat melanoma is Atezolizumab (Tecentriq).
Severe cases of melanoma can be treated through surgery. A broad local excision is used for removing melanoma and normal tissue around it. Skin grafting may be performed in order to cover wound caused due to surgery.
Chemotherapy can aid in certain situations such as metastatic melanoma. It facilitates shrinkage of melanoma tumors that have been spread to various areas of the body.
The U.S. FDA has recently approved Amtagvi (lifileucel), the very first cellular therapy meant to treat adult patients with melanoma that can’t be removed through surgery.
As per the International Agency for Research on Cancer (IARC), the year 2022 witnessed 330,000 new cases of melanoma worldwide with 60,000 individuals succumbing to it.
Increase in the incidence of skin cancer and need to combat it are thus accelerating the melanoma therapeutics market growth.
Targeted therapy means the medication interfering with function of the abnormal molecules within the cancer tumor cells in order to regulate their growth. The molecules, on having certain mutations, signal cancer cells to proliferate.
The targeted therapy is systemic. In other words, it states that drugs travel through bloodstream to every part of the body. The systemic cancer treatments help in fighting cancers spreading from original location to the other parts of the body.
About 50% of melanoma cells are known for having genetic mutations in BRAF protein. BRAF, along with MEK, are the molecules aiding in regulation of growth of cells. A BRAF mutation triggers the cells to develop on an abnormal note and divide beyond control.
The targeted therapy drugs block activity of MEK protein and mutated BRAF protein. This way, drugs stop or slow the growth of melanoma.
Along the above-mentioned lines, in March 2022, the U.S. FDA approved a new therapy for patients suffering from inoperable or metastatic melanoma. The treatment comprises two immunotherapy agents called relatimab (anti-LAG-3) and nivolumab (anti-PD-1).
Growing awareness about targeted therapy is thus expanding the melanoma therapeutics market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest anti-melanoma treatments industry analysis, North America dominated the melanoma medication landscape and the scenario is expected to remain the same during the forecast period. This is attributed to the U.S. housing the highest number of patients affected by skin cancer.
As per the American Academy of Dermatology Association (AAD) updates in 2022, skin cancer is amongst the most common cancers in the U.S. It further states that 20% of Americans will contract cancer once in their lifetime.
The American Cancer Society states that 99,780 new melanoma cases were detected in the U.S. in 2022 and 7,650 individuals succumbed to it in the same year.
Asia Pacific’s significant melanoma therapeutics market growth is ascribed to continuous increase in the incidence of skin cancer in countries such as India with the government taking measurable steps to combat it.
For instance, the National Cancer Grid, one of the initiatives undertaken by the Government of India, has come up with a novel center for digital oncology in order to enhance the quality of cancer treatment using digital technologies.
The key participants in the melanoma therapeutics market are launching new products to sustain themselves in the melanoma therapies landscape. For instance, in December 2022, Moderna, Inc. announced launching a personalized mRNA vaccine combined with Merck’s Keytruda, which is reported to be useful in cutting down on risk of fatalities in stage 3 & 4 melanoma patients by 44%.
Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Merck & Co., Inc., Amgen Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories are some of the key players covered in the melanoma therapeutics market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 6.4 Bn |
| Market Forecast (Value) in 2034 | US$ 19.2 Bn |
| Growth Rate (CAGR) | 10.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 6.4 Bn in 2023
It is projected to grow at a CAGR of 10.6% from 2024 to 2034
Rise in incidence of skin cancer and demand for targeted therapy
Hospitals & specialty clinics segment accounted for the largest share in 2023
North America was the dominant region in 2023
Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Merck & Co., Inc., Amgen Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Melanoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Melanoma Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Melanoma Therapeutics Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2020-2034
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Targeted Therapy
6.3.4. Radiation Therapy
6.3.5. Surgery
6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Melanoma Therapeutics Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Superficial Spreading Melanoma
7.3.2. Nodular Melanoma
7.3.3. Lentigo Maligna Melanoma
7.3.4. Acral Lentiginous Melanoma
7.3.5. Desmoplastic Melanoma
7.4. Market Attractiveness Analysis, by Disease Indication
8. Global Melanoma Therapeutics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals & Specialty Clinics
8.3.2. Homecare Settings
8.3.3. Others (Academic Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Melanoma Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Melanoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapy Type, 2020-2034
10.3.1. Chemotherapy
10.3.2. Immunotherapy
10.3.3. Targeted Therapy
10.3.4. Radiation Therapy
10.3.5. Surgery
10.4. Market Value Forecast, by Disease Indication, 2020-2034
10.4.1. Superficial Spreading Melanoma
10.4.2. Nodular Melanoma
10.4.3. Lentigo Maligna Melanoma
10.4.4. Acral Lentiginous Melanoma
10.4.5. Desmoplastic Melanoma
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals & Specialty Clinics
10.5.2. Homecare Settings
10.5.3. Others (Academic Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Therapy Type
10.7.2. By Disease Indication
10.7.3. By End-user
10.7.4. By Country
11. Europe Melanoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapy Type, 2020-2034
11.3.1. Chemotherapy
11.3.2. Immunotherapy
11.3.3. Targeted Therapy
11.3.4. Radiation Therapy
11.3.5. Surgery
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Superficial Spreading Melanoma
11.4.2. Nodular Melanoma
11.4.3. Lentigo Maligna Melanoma
11.4.4. Acral Lentiginous Melanoma
11.4.5. Desmoplastic Melanoma
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals & Specialty Clinics
11.5.2. Homecare Settings
11.5.3. Others (Academic Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Therapy Type
11.7.2. By Disease Indication
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Melanoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapy Type, 2020-2034
12.3.1. Chemotherapy
12.3.2. Immunotherapy
12.3.3. Targeted Therapy
12.3.4. Radiation Therapy
12.3.5. Surgery
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Superficial Spreading Melanoma
12.4.2. Nodular Melanoma
12.4.3. Lentigo Maligna Melanoma
12.4.4. Acral Lentiginous Melanoma
12.4.5. Desmoplastic Melanoma
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals & Specialty Clinics
12.5.2. Homecare Settings
12.5.3. Others (Academic Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Therapy Type
12.7.2. By Disease Indication
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Melanoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapy Type, 2020-2034
13.3.1. Chemotherapy
13.3.2. Immunotherapy
13.3.3. Targeted Therapy
13.3.4. Radiation Therapy
13.3.5. Surgery
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Superficial Spreading Melanoma
13.4.2. Nodular Melanoma
13.4.3. Lentigo Maligna Melanoma
13.4.4. Acral Lentiginous Melanoma
13.4.5. Desmoplastic Melanoma
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals & Specialty Clinics
13.5.2. Homecare Settings
13.5.3. Others (Academic Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Therapy Type
13.7.2. By Disease Indication
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Melanoma Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapy Type, 2020-2034
14.3.1. Chemotherapy
14.3.2. Immunotherapy
14.3.3. Targeted Therapy
14.3.4. Radiation Therapy
14.3.5. Surgery
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Superficial Spreading Melanoma
14.4.2. Nodular Melanoma
14.4.3. Lentigo Maligna Melanoma
14.4.4. Acral Lentiginous Melanoma
14.4.5. Desmoplastic Melanoma
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals & Specialty Clinics
14.5.2. Homecare Settings
14.5.3. Others (Academic Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Therapy Type
14.7.2. By Disease Indication
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb Company
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Amgen Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffmann-La Roche AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Abbott Laboratories
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
List of Tables
Table 01: Global Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Therapy Type, 2020-2034
Table 02: Global Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 03: Global Melanoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Therapy Type, 2020-2034
Table 07: North America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 08: North America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 09: Europe Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Therapy Type, 2020-2034
Table 11: Europe Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 12: Europe Melanoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Therapy Type, 2020-2034
Table 15: Asia Pacific Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 16: Asia Pacific Melanoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Latin America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Therapy Type, 2020-2034
Table 19: Latin America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 20: Latin America Melanoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Therapy Type, 2020-2034
Table 23: Middle East & Africa Melanoma Therapeutics Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 24: Middle East & Africa Melanoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Melanoma Therapeutics Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Melanoma Therapeutics Market Revenue (US$ Bn), by Therapy Type, 2023
Figure 03: Global Melanoma Therapeutics Market Value Share, by Therapy Type, 2023
Figure 04: Global Melanoma Therapeutics Market Revenue (US$ Bn), by Disease Indication, 2023
Figure 05: Global Melanoma Therapeutics Market Value Share, by Disease Indication, 2023
Figure 06: Global Melanoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 07: Global Melanoma Therapeutics Market Value Share, by End-user, 2023
Figure 08: Global Melanoma Therapeutics Market Value Share, by Region, 2023
Figure 09: Global Melanoma Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Melanoma Therapeutics Market Value Share Analysis, by Therapy Type, 2023 and 2034
Figure 11: Global Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Melanoma Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 13: Global Melanoma Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 14: Global Melanoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Melanoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Melanoma Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Melanoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Melanoma Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Melanoma Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Melanoma Therapeutics Market Value Share Analysis, by Therapy Type, 2023 and 2034
Figure 22: North America Melanoma Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 23: North America Melanoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Melanoma Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 26:North America Melanoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Melanoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Melanoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Melanoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Melanoma Therapeutics Market Value Share Analysis, by Therapy Type, 2023 and 2034
Figure 31: Europe Melanoma Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 32: Europe Melanoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Melanoma Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 35: Europe Melanoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Melanoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Melanoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Melanoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Melanoma Therapeutics Market Value Share Analysis, by Therapy Type, 2023 and 2034
Figure 40: Asia Pacific Melanoma Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 41: Asia Pacific Melanoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Melanoma Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 44: Asia Pacific Melanoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Melanoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Melanoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Melanoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Melanoma Therapeutics Market Value Share Analysis, by Therapy Type, 2023 and 2034
Figure 49: Latin America Melanoma Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 50: Latin America Melanoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Melanoma Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 53: Latin America Melanoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Melanoma Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Melanoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Melanoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Melanoma Therapeutics Market Value Share Analysis, by Therapy Type, 2023 and 2034
Figure 58: Middle East & Africa Melanoma Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 59: Middle East & Africa Melanoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Melanoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Melanoma Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 62: Middle East & Africa Melanoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Melanoma Therapeutics Market
